Portal Notfall Aufnahme

Universitätsklinik für Innere Medizin – Onkologie und Hämatologie


Zahlen, Daten, Fakten

48 stationäre Betten
10 teilstationäre Betten
3 Stationen
104 Mitarbeiterinnen & Mitarbeiter

Im Jahr 2019

915Behandlungsfälle (DRG)
153teilstationäre Behandlungstage
114Knochenmarktransplantationen
insgesamt, davon...
78autologe Stammzelltransplantationen
36allogene Stammzelltransplantationen


Ärztliches Team

 

Klinikdirektor

Univ.-Prof. Dr. med. Claus-Henning Köhne

Klinikdirektor der Universitätsklinik für Innere Medizin - Onkologie und Hämatologie

Facharzt für Innere Medizin, Schwerpunkt Hämatologie und Internistische Onkologie

Telefon: (0441) 403-2611

Telefax: (0441) 403-2654

E-Mail: onkologie@klinikum-oldenburg.de


Beruflicher Lebenslauf:


Name:Univ.-Prof. Dr. med. Claus-Henning Köhne
Studium: 
1978 – 1985Medizinische Hochschule Hannover
1982 – 1983University of Glasgow, Scotland, DAAD-Grand
Vorherige Positionen:
1986 – 1987Kardiologie und Gastroenterologie
Robert-Koch-Krankenhaus, Gehrden
1988 – 1995Medizinische Hochschule Hannover
1995 – 1998Oberarzt Robert-Rössle-Klinik, Abt.. Hämatologie / Onkologie und Tumorimmunologie, Charite, Humboldt-University Berlin, (Direktor: Univ. Prof. Dr.med. Bernd Dörken)
1998 – 2001Oberarzt Universität Rostock, Klinik und Poliklinik für Innere Medizin, Abt. Hämatologie / Onkologie (Direktor: Univ. Prof. Dr. med. Mathias Freund)
2001 – 2004

C3 Professur Innere Medizin mit dem Schwerpunkt Internistische Onkologie an der Medizinischen Klinik und Poliklinik I, Universitätsklinik Carl Gustav Carus der TU- Dresden (Direktor: Univ. Prof. Dr. med. Gerhard Ehninger)

Jetzige Position:

Direktor Universitätsklinik für Innere Medizin II - Onkologie und Hämatologie am Klinikum Oldenburg, Rahel- Straus- Str. 10, 26133 Oldenburg

Qualifikationen:
1985Approbation
1987Promotion
1995
  • Facharzt für Innere Medizin
  • Facharzt für Innere Medizin/Hämatologie/Internistische Onkologie
  • Internistische Onkologie, Examen der European Society of Medical Oncology (ESMO)
2000

PD Dr. med. habil. für Innere Medizin, Universität Rostock

2018
Berufung auf die Professur für Innere Medizin der Fakultät VI – Medizin und Gesundheitswissenschaften der Carl von Ossietzky Universität Oldenburg im November 2018
Mitgliedschaften:
·         AACR (American Association of Cancer Research)
·         AIO (Arbeitsgemeinschaft Internistische Onkologie)
·         ASCO (American Society of Clinical Oncology)
·         DKG (Deutsche Krebsgesellschaft)
·         DGHO (Deutsche Gesellschaft für Hämatologie und Onkologie)
·         EORTC Gastrointestinal Group (European Organisation for Research and Treatment of cancer)
·         ESMO (European Society of Medical Oncology)
·         Leiter der Wilsede-Schule für Onkologie, Hämatologie, Palliativmedizin, Wilsede-Akademie
·         SIOG (International Society of Geriatric Oncology)
Mitarbeit in wissenschaftlichen Gremien/Fachgesellschaften
·         Gründungsmitglied der Pan-European-Trial for adjuvant Colon Cancer (PETACC) Initiative
·         Studienkoordinator der PETACC 2-Studie
·         Studienkoordinator der EORTC Studien #40952, 40986, 40015
·         Secretary EORTC GI Group (2001 – 2007)
·         Editorial board member von ‘Annals of Oncology’
·         Berater der Europäischen Zulassungsbehörde EMA (London)
  • Berater des Institutes für angewandte Qualitätsförderung und Forschung im Gesundheitswesen AQUA (Göttingen)


Veröffentlichungen:

1: Köhne CH, Karthaus M, Mineur L, Thaler J, Van den Eynde M, Gallego J, Koukakis
R, Berkhout M, Hofheinz RD. Impact of Primary Tumour Location and Early Tumour
Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer
Following First-Line FOLFIRI Plus Panitumumab. Drugs R D. 2019 Sep;19(3):267-275.
doi: 10.1007/s40268-019-0278-8. PubMed PMID: 31300973; PubMed Central PMCID:
PMC6738356.
 
 
2: Noske A, Möbus V, Weber K, Schmatloch S, Weichert W, Köhne CH, Solbach C,
Ingold Heppner B, Steiger K, Müller V, Fasching P, Karn T, van Mackelenbergh M,
Marmé F, Schmitt WD, Schem C, Stickeler E, Loibl S, Denkert C. Relevance of
tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk,
nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive
study. Eur J Cancer. 2019 Jun;114:76-88. doi: 10.1016/j.ejca.2019.04.010. Epub
2019 May 7. PubMed PMID: 31075727.
 
 
3: Michel C, Burchert A, Hochhaus A, Saussele S, Neubauer A, Lauseker M, Krause
SW, Kolb HJ, Hossfeld DK, Nerl C, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius
A, Haferlach C, Schlegelberger B, Balleisen L, Goebeler ME, Hänel M, Ho A,
Dengler J, Falge C, Möhle R, Kremers S, Kneba M, Stegelmann F, Köhne CH,
Lindemann HW, Waller CF, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J,
Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag
R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P,
Verbeek W, Eckart MJ, Gassmann W, Schenk M, Brossart P, Wündisch T, Geer T,
Bildat S, Schäfer E, Hasford J, Hehlmann R, Pfirrmann M. Imatinib dose reduction
in major molecular response of chronic myeloid leukemia: results from the German
Chronic Myeloid Leukemia-Study IV. Haematologica. 2019 May;104(5):955-962. doi:
10.3324/haematol.2018.206797. Epub 2018 Dec 4. PubMed PMID: 30514803; PubMed
Central PMCID: PMC6518910.
 
 
4: Pfeiffer P, Köhne CH, Qvortrup C. The changing face of treatment for
metastatic colorectal cancer. Expert Rev Anticancer Ther. 2019 Jan;19(1):61-70.
doi: 10.1080/14737140.2019.1543593. Epub 2018 Nov 9. PubMed PMID: 30381969.
 
 
5: Fokas E, Fietkau R, Hartmann A, Hohenberger W, Grützmann R, Ghadimi M, Liersch
T, Ströbel P, Grabenbauer GG, Graeven U, Hofheinz RD, Köhne CH, Wittekind C,
Sauer R, Kaufmann M, Hothorn T, Rödel C; German Rectal Cancer Study Group.
Neoadjuvant rectal score as individual-level surrogate for disease-free survival
in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial. Ann Oncol.
2018 Jul 1;29(7):1521-1527. doi: 10.1093/annonc/mdy143. PubMed PMID: 29718095.
 
 
6: Goey KKH, Mahmoud R, Sørbye H, Glimelius B, Köhne CH, Sargent DJ, Punt CJA,
van Oijen MGH, Koopman M. Reporting of patient characteristics and stratification
factors in phase 3 trials investigating first-line systemic treatment of
metastatic colorectal cancer: A systematic review. Eur J Cancer. 2018
Jun;96:115-124. doi: 10.1016/j.ejca.2018.03.026. Epub 2018 May 2. PubMed PMID:
29729562.
 
 
7: Siena S, Rivera F, Taieb J, Peeters M, Prenen H, Koukakis R, Demonty G, Köhne
CH. Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer
Classified According to Köhne Prognostic Category and BRAF Mutation Status. Clin
Colorectal Cancer. 2018 Mar;17(1):50-57.e8. doi: 10.1016/j.clcc.2017.09.006. Epub
2017 Sep 28. PubMed PMID: 29096990.
 
 
8: van Rossum AGJ, Schouten PC, Weber KE, Nekljudova V, Denkert C, Solbach C,
Köhne CH, Thomssen C, Forstbauer H, Hoffmann G, Kohls A, Schmatloch S, Schem C,
von Minckwitz G, Karn T, Möbus VJ, Linn SC, Loibl S, Marmé F. BRCA1-like profile
is not significantly associated with survival benefit of non-myeloablative
intensified chemotherapy in the GAIN randomized controlled trial. Breast Cancer
Res Treat. 2017 Dec;166(3):775-785. doi: 10.1007/s10549-017-4444-9. Epub 2017 Aug
18. PubMed PMID: 28822007.
 
 
9: Chavan A, Schumann-Binarsch S, Schmuck B, Oltmer F, Geisthoff U, Hoppe F,
Wirsching K, Klempnauer J, Manns M, Philip Thomas R, Köhne CH. Emerging role of
bevacizumab in management of patients with symptomatic hepatic involvement in
Hereditary Hemorrhagic Telangiectasia. Am J Hematol. 2017 Nov;92(11):E641-E644.
doi: 10.1002/ajh.24878. Epub 2017 Aug 24. PubMed PMID: 28776732.
 
 
10: Wattad M, Weber D, Döhner K, Krauter J, Gaidzik VI, Paschka P, Heuser M, Thol
F, Kindler T, Lübbert M, Salih HR, Kündgen A, Horst HA, Brossart P, Götze K,
Nachbaur D, Köhne CH, Ringhoffer M, Wulf G, Held G, Salwender H, Benner A, Ganser
A, Döhner H, Schlenk RF. Impact of salvage regimens on response and overall
survival in acute myeloid leukemia with induction failure. Leukemia. 2017
Jun;31(6):1306-1313. doi: 10.1038/leu.2017.23. Epub 2017 Jan 19. PubMed PMID:
28138160.
 
 
11: Jaramillo S, Benner A, Krauter J, Martin H, Kindler T, Bentz M, Salih HR,
Held G, Köhne CH, Götze K, Lübbert M, Kündgen A, Brossart P, Wattad M, Salwender
H, Hertenstein B, Nachbaur D, Wulf G, Horst HA, Kirchen H, Fiedler W, Raghavachar
A, Russ G, Kremers S, Koller E, Runde V, Heil G, Weber D, Göhring G, Döhner K,
Ganser A, Döhner H, Schlenk RF. Condensed versus standard schedule of high-dose
cytarabine consolidation therapy with pegfilgrastim growth factor support in
acute myeloid leukemia. Blood Cancer J. 2017 May 26;7(5):e564. doi:
10.1038/bcj.2017.45. PubMed PMID: 28548643; PubMed Central PMCID: PMC5518888.
 
 
12: Jahn N, Agrawal M, Bullinger L, Weber D, Corbacioglu A, Gaidzik VI,
Schmalbrock L, Thol F, Heuser M, Krauter J, Göhring G, Kündgen A, Fiedler W,
Wattad M, Held G, Köhne CH, Horst HA, Lübbert M, Ganser A, Schlenk RF, Döhner H,
Döhner K, Paschka P. Incidence and prognostic impact of ASXL2 mutations in adult
acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the
German-Austrian AML Study Group. Leukemia. 2017 Apr;31(4):1012-1015. doi:
10.1038/leu.2017.18. Epub 2017 Jan 16. PubMed PMID: 28090090.
 
 
13: Gerullis H, Wawroschek F, Köhne CH, Ecke TH. Vinflunine in the treatment of
advanced urothelial cancer: clinical evidence and experience. Ther Adv Urol. 2017
Jan;9(1):28-35. doi: 10.1177/1756287216677903. Epub 2016 Nov 21. Review. PubMed
PMID: 28042310; PubMed Central PMCID: PMC5167074.
 
 
14: Schlenk RF, Lübbert M, Benner A, Lamparter A, Krauter J, Herr W, Martin H,
Salih HR, Kündgen A, Horst HA, Brossart P, Götze K, Nachbaur D, Wattad M, Köhne
CH, Fiedler W, Bentz M, Wulf G, Held G, Hertenstein B, Salwender H, Gaidzik VI,
Schlegelberger B, Weber D, Döhner K, Ganser A, Döhner H; German-Austrian Acute
Myeloid Leukemia Study Group. All-trans retinoic acid as adjunct to intensive
treatment in younger adult patients with acute myeloid leukemia: results of the
randomized AMLSG 07-04 study. Ann Hematol. 2016 Dec;95(12):1931-1942. Epub 2016
Oct 3. PubMed PMID: 27696203; PubMed Central PMCID: PMC5093206.
 
 
15: Karthaus M, Hofheinz RD, Mineur L, Letocha H, Greil R, Thaler J, Fernebro E,
Oliner KS, Boedigheimer M, Twomey B, Zhang Y, Demonty G, Köhne CH. Impact of
tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients
with metastatic colorectal cancer. Br J Cancer. 2016 Nov 8;115(10):1215-1222.
doi: 10.1038/bjc.2016.343. Epub 2016 Oct 20. PubMed PMID: 27764839; PubMed
Central PMCID: PMC5104899.
 
 
16: Gaidzik VI, Teleanu V, Papaemmanuil E, Weber D, Paschka P, Hahn J,
Wallrabenstein T, Kolbinger B, Köhne CH, Horst HA, Brossart P, Held G, Kündgen A,
Ringhoffer M, Götze K, Rummel M, Gerstung M, Campbell P, Kraus JM, Kestler HA,
Thol F, Heuser M, Schlegelberger B, Ganser A, Bullinger L, Schlenk RF, Döhner K,
Döhner H. RUNX1 mutations in acute myeloid leukemia are associated with distinct
clinico-pathologic and genetic features. Leukemia. 2016 Nov;30(11):2282. doi:
10.1038/leu.2016.207. PubMed PMID: 27804971.
 
 
17: Theis F, Corbacioglu A, Gaidzik VI, Paschka P, Weber D, Bullinger L, Heuser
M, Ganser A, Thol F, Schlegelberger B, Göhring G, Köhne CH, Germing U, Brossart
P, Horst HA, Haase D, Götze K, Ringhoffer M, Fiedler W, Nachbaur D, Kindler T,
Held G, Lübbert M, Wattad M, Salih HR, Krauter J, Döhner H, Schlenk RF, Döhner K.
Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring
CEBPA mutations: a study of the AML study group. Leukemia. 2016
Nov;30(11):2248-2250. doi: 10.1038/leu.2016.185. Epub 2016 Jul 4. PubMed PMID:
27375010.
 
 
18: Gaidzik VI, Teleanu V, Papaemmanuil E, Weber D, Paschka P, Hahn J,
Wallrabenstein T, Kolbinger B, Köhne CH, Horst HA, Brossart P, Held G, Kündgen A,
Ringhoffer M, Götze K, Rummel M, Gerstung M, Campbell P, Kraus JM, Kestler HA,
Thol F, Heuser M, Schlegelberger B, Ganser A, Bullinger L, Schlenk RF, Döhner K,
Döhner H. RUNX1 mutations in acute myeloid leukemia are associated with distinct
clinico-pathologic and genetic features. Leukemia. 2016 Nov;30(11):2160-2168.
doi: 10.1038/leu.2016.126. Epub 2016 May 3. Erratum in: Leukemia. 2016
Nov;30(11):2282. PubMed PMID: 27137476.
 
 
19: Köhne CH, Poston G, Folprecht G, Ciardiello F, Ronga P, Beier F, Van Cutsem
E. FOLFIRI plus cetuximab in patients with liver-limited or non-liver-limited RAS
wild-type metastatic colorectal cancer: A retrospective subgroup analysis of the
CRYSTAL study. Eur J Surg Oncol. 2016 Oct;42(10):1540-7. doi:
10.1016/j.ejso.2016.05.038. Epub 2016 Jun 23. PubMed PMID: 27575968.
 
 
20: Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz
JP, Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts
J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R,
Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR,
Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan
PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV Jr,
Jost L, Keilholz U, Khan S, Kiss A, Köhne CH, Kunstfeld R, Lenz HJ, Lichtman S,
Licitra L, Lion T, Litière S, Liu L, Loehrer PJ, Markham MJ, Markman B,
Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen
T, Ohe Y, Öberg K, Palumbo A, Peccatori FA, Pfeilstöcker M, Raut C, Remick SC,
Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M,
Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F,
Strasser F, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E,
Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y. ESMO / ASCO Recommendations
for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open. 2016 Sep
29;1(5):e000097. eCollection 2016. Review. PubMed PMID: 27843641; PubMed Central
PMCID: PMC5070299.
 
 
21: Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D,
Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, DHoore A,
Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T,
Haustermans K, Heinemann V, Hoff P, Köhne CH, Labianca R, Laurent-Puig P, Ma B,
Maughan T, Muro K, Normanno N, Österlund P, Oyen WJ, Papamichael D,
Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R,
Scheithauer W, Schmoll HJ, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T,
Zaanan A, Arnold D. ESMO consensus guidelines for the management of patients with
metastatic colorectal cancer. Ann Oncol. 2016 Aug;27(8):1386-422. doi:
10.1093/annonc/mdw235. Epub 2016 Jul 5. PubMed PMID: 27380959.
 
 
22: Hütter-Krönke ML, Benner A, Döhner K, Krauter J, Weber D, Moessner M, Köhne
CH, Horst HA, Schmidt-Wolf IG, Rummel M, Götze K, Koller E, Petzer AL, Salwender
H, Fiedler W, Kirchen H, Haase D, Kremers S, Theobald M, Matzdorff AC, Ganser A,
Döhner H, Schlenk RF. Salvage therapy with high-dose cytarabine and mitoxantrone
in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute
myeloid leukemia refractory to first induction therapy. Haematologica. 2016
Jul;101(7):839-45. doi: 10.3324/haematol.2015.141622. Epub 2016 Apr 1. PubMed
PMID: 27036160; PubMed Central PMCID: PMC5004463.
 
 
23: Gelderblom H, Köhne CH, Launay-Vacher V, van Leeuwen RW. Drug-drug
interactions associated with kinase inhibitors: highlighting a new resource for
oncologists and clinical pharmacists. Ann Oncol. 2016 Apr;27(4):752. doi:
10.1093/annonc/mdw019. Epub 2016 Jan 19. PubMed PMID: 26787233.
 
 
24: Fabarius A, Kalmanti L, Dietz CT, Lauseker M, Rinaldetti S, Haferlach C,
Göhring G, Schlegelberger B, Jotterand M, Hanfstein B, Seifarth W, Hänel M, Köhne
CH, Lindemann HW, Berdel WE, Staib P, Müller MC, Proetel U, Balleisen L, Goebeler
ME, Dengler J, Falge C, Kanz L, Burchert A, Kneba M, Stegelmann F, Pfreundschuh
M, Waller CF, Spiekermann K, Brümmendorf TH, Edinger M, Hofmann WK, Pfirrmann M,
Hasford J, Krause S, Hochhaus A, Saußele S, Hehlmann R; SAKK and the German CML
Study Group. Impact of unbalanced minor route versus major route karyotypes at
diagnosis on prognosis of CML. Ann Hematol. 2015 Dec;94(12):2015-24. doi:
10.1007/s00277-015-2494-9. Epub 2015 Sep 18. PubMed PMID: 26385387.
 
 
25: Köhne CH. Is Progression-Free Survival the Right End Point in Trials of
Patients With Clearly Resectable, Borderline Resectable, and Unresectable
Liver-Limited Colorectal Cancer? J Clin Oncol. 2015 Jul 20;33(21):2406-7. doi:
10.1200/JCO.2014.60.7044. Epub 2015 Jun 1. PubMed PMID: 26033812.
 
 
26: Bokemeyer C, Köhne CH, Ciardiello F, Lenz HJ, Heinemann V, Klinkhardt U,
Beier F, Duecker K, van Krieken JH, Tejpar S. FOLFOX4 plus cetuximab treatment
and RAS mutations in colorectal cancer. Eur J Cancer. 2015 Jul;51(10):1243-52.
doi: 10.1016/j.ejca.2015.04.007. Epub 2015 Apr 30. PubMed PMID: 25937522.
 
 
27: Argilés G, Saunders MP, Rivera F, Sobrero A, Benson A 3rd, Guillén Ponce C,
Cascinu S, Van Cutsem E, Macpherson IR, Strumberg D, Köhne CH, Zalcberg J, Wagner
A, Luigi Garosi V, Grunert J, Tabernero J, Ciardiello F. Regorafenib plus
modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase
II trial. Eur J Cancer. 2015 May;51(8):942-9. doi: 10.1016/j.ejca.2015.02.013.
Epub 2015 Mar 25. PubMed PMID: 25818084.
 
 
28: Papamichael D, Audisio RA, Glimelius B, de Gramont A, Glynne-Jones R, Haller
D, Köhne CH, Rostoft S, Lemmens V, Mitry E, Rutten H, Sargent D, Sastre J,
Seymour M, Starling N, Van Cutsem E, Aapro M. Treatment of colorectal cancer in
older patients: International Society of Geriatric Oncology (SIOG) consensus
recommendations 2013. Ann Oncol. 2015 Mar;26(3):463-76. doi:
10.1093/annonc/mdu253. Epub 2014 Jul 11. Review. PubMed PMID: 25015334.
 
 
29: Paschka P, Schlenk RF, Gaidzik VI, Herzig JK, Aulitzky T, Bullinger L, Späth
D, Teleanu V, Kündgen A, Köhne CH, Brossart P, Held G, Horst HA, Ringhoffer M,
Götze K, Nachbaur D, Kindler T, Heuser M, Thol F, Ganser A, Döhner H, Döhner K.
ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by
the German-Austrian Acute Myeloid Leukemia Study Group. Haematologica. 2015
Mar;100(3):324-30. doi: 10.3324/haematol.2014.114157. Epub 2015 Jan 16. PubMed
PMID: 25596267; PubMed Central PMCID: PMC4349270.
 
 
30: Van Cutsem E, Lenz HJ, Köhne CH, Heinemann V, Tejpar S, Melezínek I, Beier F,
Stroh C, Rougier P, van Krieken JH, Ciardiello F. Fluorouracil, leucovorin, and
irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J
Clin Oncol. 2015 Mar 1;33(7):692-700. doi: 10.1200/JCO.2014.59.4812. Epub 2015
Jan 20. PubMed PMID: 25605843.
 
 
31: Yalcin S, Trad D, Kader YA, Halawani H, Demir OG, Mall R, Meshcheryakov A,
Nasr F, Nosworthy A, Osinsky D, Tumanova A, Turhal S, Tejpar S, Köhne CH.
Personalized treatment is better than one treatment fits all in the management of
patients with mCRC: a consensus statement. Future Oncol. 2014 Dec;10(16):2643-57.
doi: 10.2217/fon.14.203. Review. PubMed PMID: 25531050.
 
 
32: Cheng AL, Li J, Vaid AK, Ma BB, Teh C, Ahn JB, Bello M, Charoentum C, Chen
LT, de Lima Lopes G Jr, Ho GF, Kong HL, Lam KO, Liu TS, Park YS, Sriuranpong V,
Sudoyo AW, Wang JY, Zhang J, Zhang SZ, Ciardiello F, Köhne CH, Shaw M, Kim TW.
Adaptation of international guidelines for metastatic colorectal cancer: an asian
consensus. Clin Colorectal Cancer. 2014 Sep;13(3):145-55. doi:
10.1016/j.clcc.2014.06.004. Epub 2014 Jun 26. PubMed PMID: 25209093.
 
 
33: Vogt V, Schick J, Ansprenger C, Braeu M, Kroell T, Kraemer D, Köhne CH,
Hausmann A, Buhmann R, Tischer J, Schmetzer H. Profiles of activation,
differentiation-markers, or β-integrins on T cells contribute to predict T cells
antileukemic responses after stimulation with leukemia-derived dendritic cells. J
Immunother. 2014 Jul-Aug;37(6):331-47. doi: 10.1097/CJI.0000000000000037. PubMed
PMID: 24911794.
 
 
34: Tassara M, Döhner K, Brossart P, Held G, Götze K, Horst HA, Ringhoffer M,
Köhne CH, Kremers S, Raghavachar A, Wulf G, Kirchen H, Nachbaur D, Derigs HG,
Wattad M, Koller E, Brugger W, Matzdorff A, Greil R, Heil G, Paschka P, Gaidzik
VI, Göttlicher M, Döhner H, Schlenk RF. Valproic acid in combination with
all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older
patients. Blood. 2014 Jun 26;123(26):4027-36. doi: 10.1182/blood-2013-12-546283.
Epub 2014 May 5. Erratum in: Blood. 2015 May 7;125(19):3037. PubMed PMID:
24797300.
 
 
35: Metzner B, Müller TH, Gebauer W, Casper J, Kraemer D, Rosien B,
Schumann-Binarsch S, Thole R, Köhne CH, Dreyling M, Hoster E, Pott C. Long-term
clinical and molecular remissions in patients with mantle cell lymphoma following
high-dose therapy and autologous stem cell transplantation. Ann Hematol. 2014
May;93(5):803-10. doi: 10.1007/s00277-013-1976-x. Epub 2013 Dec 13. PubMed PMID:
24337447.
 
 
36: Folprecht G, Gruenberger T, Bechstein W, Raab HR, Weitz J, Lordick F,
Hartmann JT, Stoehlmacher-Williams J, Lang H, Trarbach T, Liersch T, Ockert D,
Jaeger D, Steger U, Suedhoff T, Rentsch A, Köhne CH. Survival of patients with
initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab
or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Ann Oncol.
2014 May;25(5):1018-25. doi: 10.1093/annonc/mdu088. Epub 2014 Feb 27. PubMed
PMID: 24585720.
 
 
37: Regierer AC, Wolters R, Ufen MP, Weigel A, Novopashenny I, Köhne CH, Samonigg
H, Eucker J, Possinger K, Wischnewsky MB. An internally and externally validated
prognostic score for metastatic breast cancer: analysis of 2269 patients. Ann
Oncol. 2014 Mar;25(3):633-8. doi: 10.1093/annonc/mdt539. Epub 2013 Dec 23. PubMed
PMID: 24368402; PubMed Central PMCID: PMC4433507.
 
 
38: Ufen MP, Köhne CH, Wischneswky M, Wolters R, Novopashenny I, Fischer J,
Constantinidou M, Possinger K, Regierer AC. Metastatic breast cancer: are we
treating the same patients as in the past? Ann Oncol. 2014 Jan;25(1):95-100. doi:
10.1093/annonc/mdt429. Epub 2013 Nov 24. PubMed PMID: 24276026.
 
 
39: Köhne CH. Successes and limitations of targeted cancer therapy in colon
cancer. Prog Tumor Res. 2014;41:36-50. doi: 10.1159/000356436. Epub 2014 Feb 17.
Review. PubMed PMID: 24727985.
 
 
40: Casper J, Schumann-Binarsch S, Köhne CH. Pazopanib versus sunitinib in renal
cancer. N Engl J Med. 2013 Nov 14;369(20):1969. doi: 10.1056/NEJMc1311795. PubMed
PMID: 24224638.
 
 
41: Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, de Azambuja E, Procter M, Suter
TM, Jackisch C, Cameron D, Weber HA, Heinzmann D, Dal Lago L, McFadden E, Dowsett
M, Untch M, Gianni L, Bell R, Köhne CH, Vindevoghel A, Andersson M, Brunt AM,
Otero-Reyes D, Song S, Smith I, Leyland-Jones B, Baselga J; Herceptin Adjuvant
(HERA) Trial Study Team. 2 years versus 1 year of adjuvant trastuzumab for
HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.
Lancet. 2013 Sep 21;382(9897):1021-8. doi: 10.1016/S0140-6736(13)61094-6. Epub
2013 Jul 18. PubMed PMID: 23871490.
 
 
42: Schultheis B, Folprecht G, Kuhlmann J, Ehrenberg R, Hacker UT, Köhne CH,
Kornacker M, Boix O, Lettieri J, Krauss J, Fischer R, Hamann S, Strumberg D,
Mross KB. Regorafenib in combination with FOLFOX or FOLFIRI as first- or
second-line treatment of colorectal cancer: results of a multicenter, phase Ib
study. Ann Oncol. 2013 Jun;24(6):1560-7. doi: 10.1093/annonc/mdt056. Epub 2013
Mar 13. PubMed PMID: 23493136; PubMed Central PMCID: PMC3660081.
 
 
43: Metzner B, Pott C, Müller TH, Gebauer W, Casper J, Kraemer D, Rosien B,
Schumann-Binarsch S, Thole R, Köhne CH. Long-term clinical and molecular
remissions in patients with follicular lymphoma following high-dose therapy and
autologous stem cell transplantation. Ann Oncol. 2013 Jun;24(6):1609-15. doi:
10.1093/annonc/mds657. Epub 2013 Feb 7. PubMed PMID: 23393125.
 
 
44: Tabernero J, Garcia-Carbonero R, Cassidy J, Sobrero A, Van Cutsem E, Köhne
CH, Tejpar S, Gladkov O, Davidenko I, Salazar R, Vladimirova L, Cheporov S,
Burdaeva O, Rivera F, Samuel L, Bulavina I, Potter V, Chang YL, Lokker NA,
ODwyer PJ. Sorafenib in combination with oxaliplatin, leucovorin, and
fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal
cancer: the RESPECT trial. Clin Cancer Res. 2013 May 1;19(9):2541-50. doi:
10.1158/1078-0432.CCR-13-0107. Epub 2013 Mar 26. PubMed PMID: 23532888.
 
 
45: Köhne CH, Bedenne L, Carrato A, Bouché O, Popov I, Gaspà L, Valladares M,
Rougier P, Gog C, Reichardt P, Wils J, Pignatti F, Biertz F. A randomised phase
III intergroup trial comparing high-dose infusional 5-fluorouracil with or
without folinic acid with standard bolus 5-fluorouracil/folinic acid in the
adjuvant treatment of stage III colon cancer: the Pan-European Trial in Adjuvant
Colon Cancer 2 study. Eur J Cancer. 2013 May;49(8):1868-75. doi:
10.1016/j.ejca.2013.01.030. Epub 2013 Apr 6. PubMed PMID: 23571150.
 
 
46: Schick J, Vogt V, Zerwes M, Kroell T, Kraemer D, Köhne CH, Hausmann A,
Buhmann R, Tischer J, Schmetzer H. Antileukemic T-cell responses can be predicted
by the composition of specific regulatory T-cell subpopulations. J Immunother.
2013 May;36(4):223-37. doi: 10.1097/CJI.0b013e31829180e7. PubMed PMID: 23603857.
 
 
47: Paschka P, Du J, Schlenk RF, Gaidzik VI, Bullinger L, Corbacioglu A, Späth D,
Kayser S, Schlegelberger B, Krauter J, Ganser A, Köhne CH, Held G, von
Lilienfeld-Toal M, Kirchen H, Rummel M, Götze K, Horst HA, Ringhoffer M, Lübbert
M, Wattad M, Salih HR, Kündgen A, Döhner H, Döhner K. Secondary genetic lesions
in acute myeloid leukemia with inv(16) or t(16;16): a study of the
German-Austrian AML Study Group (AMLSG). Blood. 2013 Jan 3;121(1):170-7. doi:
10.1182/blood-2012-05-431486. Epub 2012 Oct 31. PubMed PMID: 23115274.
 
 
48: Ediebah DE, Coens C, Maringwa JT, Quinten C, Zikos E, Ringash J, King M,
Gotay C, Flechtner HH, Schmucker von Koch J, Weis J, Smit EF, Köhne CH, Bottomley
A; Gastro-Intestinal Tract Cancer Cooperative Group; Lung Cancer Cooperative
Group; Quality of Life Department and Patient Reported Outcome and Behavioural
Evidence (PROBE). Effect of completion-time windows in the analysis of
health-related quality of life outcomes in cancer patients. Ann Oncol. 2013
Jan;24(1):231-7. doi: 10.1093/annonc/mds220. Epub 2012 Aug 30. PubMed PMID:
22935549; PubMed Central PMCID: PMC3525133.
 
 
49: Láng I, Köhne CH, Folprecht G, Rougier P, Curran D, Hitre E, Sartorius U,
Griebsch I, Van Cutsem E. Quality of life analysis in patients with KRAS
wild-type metastatic colorectal cancer treated first-line with cetuximab plus
irinotecan, fluorouracil and leucovorin. Eur J Cancer. 2013 Jan;49(2):439-48.
doi: 10.1016/j.ejca.2012.08.023. Epub 2012 Oct 29. PubMed PMID: 23116683.
 
 
50: Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K,
Nordlinger B, van de Velde CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG,
Arnold D, Ciardiello F, Hoff P, Kerr D, Köhne CH, Labianca R, Price T,
Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard
JY, El Ghazaly H, Gallardo J, Garin A, Glynne-Jones R, Jordan K, Meshcheryakov A,
Papamichail D, Pfeiffer P, Souglakos I, Turhal S, Cervantes A. ESMO Consensus
Guidelines for management of patients with colon and rectal cancer. a
personalized approach to clinical decision making. Ann Oncol. 2012
Oct;23(10):2479-516. PubMed PMID: 23012255.
 
 
51: Thaler J, Karthaus M, Mineur L, Greil R, Letocha H, Hofheinz R, Fernebro E,
Gamelin E, Baños A, Köhne CH. Skin toxicity and quality of life in patients with
metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment
in a single-arm phase II study. BMC Cancer. 2012 Sep 29;12:438. doi:
10.1186/1471-2407-12-438. PubMed PMID: 23020584; PubMed Central PMCID:
PMC3520865.
 
 
52: Köhne CH. Current stages of adjuvant treatment of colon cancer. Ann Oncol.
2012 Sep;23 Suppl 10:x71-6. PubMed PMID: 22987996.
 
 
53: Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M,
Celik I, Köhne CH. Addition of cetuximab to chemotherapy as first-line treatment
for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL
and OPUS randomised clinical trials. Eur J Cancer. 2012 Jul;48(10):1466-75. doi:
10.1016/j.ejca.2012.02.057. Epub 2012 Mar 23. PubMed PMID: 22446022.
 
 
54: Gottschling S, Herpel E, Eberhardt WE, Heigener DF, Fischer JR, Köhne CH,
Kortsik C, Kuhnt T, Muley T, Meister M, Bischoff HG, Klein P, Moldenhauer I,
Schnabel PA, Thomas M, Penzel R. The gefitinib long-term responder (LTR)--a
cancer stem-like cell story? Insights from molecular analyses of German long-term
responders treated in the IRESSA expanded access program (EAP). Lung Cancer. 2012
Jul;77(1):183-91. doi: 10.1016/j.lungcan.2012.03.003. Epub 2012 Apr 7. PubMed
PMID: 22483783.
 
 
55: Gaidzik VI, Paschka P, Späth D, Habdank M, Köhne CH, Germing U, von
Lilienfeld-Toal M, Held G, Horst HA, Haase D, Bentz M, Götze K, Döhner H, Schlenk
RF, Bullinger L, Döhner K. TET2 mutations in acute myeloid leukemia (AML):
results from a comprehensive genetic and clinical analysis of the AML study
group. J Clin Oncol. 2012 Apr 20;30(12):1350-7. doi: 10.1200/JCO.2011.39.2886.
Epub 2012 Mar 19. PubMed PMID: 22430270.
 
 
56: Peeters M, Cohn A, Köhne CH, Douillard JY. Panitumumab in combination with
cytotoxic chemotherapy for the treatment of metastatic colorectal carcinoma. Clin
Colorectal Cancer. 2012 Mar;11(1):14-23. doi: 10.1016/j.clcc.2011.06.010. Epub
2011 Sep 16. Review. PubMed PMID: 21925954.
 
 
57: Kayser S, Zucknick M, Döhner K, Krauter J, Köhne CH, Horst HA, Held G, von
Lilienfeld-Toal M, Wilhelm S, Rummel M, Germing U, Götze K, Nachbaur D,
Schlegelberger B, Göhring G, Späth D, Morlok C, Teleanu V, Ganser A, Döhner H,
Schlenk RF; German-Austrian AML Study Group. Monosomal karyotype in adult acute
myeloid leukemia: prognostic impact and outcome after different treatment
strategies. Blood. 2012 Jan 12;119(2):551-8. doi: 10.1182/blood-2011-07-367508.
Epub 2011 Nov 16. PubMed PMID: 22096250.
 
 
58: Köhne CH, Hofheinz R, Mineur L, Letocha H, Greil R, Thaler J, Fernebro E,
Gamelin E, Decosta L, Karthaus M. First-line panitumumab plus
irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic
colorectal cancer. J Cancer Res Clin Oncol. 2012 Jan;138(1):65-72. doi:
10.1007/s00432-011-1061-6. Epub 2011 Sep 30. PubMed PMID: 21960318.
 
 
59: Pordzik S, Petrovici K, Schmid C, Kroell T, Schweiger C, Köhne CH, Schmetzer
H. Expression and prognostic value of FAS receptor/FAS ligand and TrailR1/TrailR2
in acute myeloid leukemia. Hematology. 2011 Nov;16(6):341-50. doi:
10.1179/102453311X13127324303353. PubMed PMID: 22183068.
 
 
60: Blanke CD, Bot BM, Thomas DM, Bleyer A, Kohne CH, Seymour MT, de Gramont A,
Goldberg RM, Sargent DJ. Impact of young age on treatment efficacy and safety in
advanced colorectal cancer: a pooled analysis of patients from nine first-line
phase III chemotherapy trials. J Clin Oncol. 2011 Jul 10;29(20):2781-6. doi:
10.1200/JCO.2010.33.5281. Epub 2011 Jun 6. PubMed PMID: 21646604; PubMed Central
PMCID: PMC4874194.
 
 
61: Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S,
Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I,
Rougier P, Ciardiello F. Cetuximab plus irinotecan, fluorouracil, and leucovorin
as first-line treatment for metastatic colorectal cancer: updated analysis of
overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol.
2011 May 20;29(15):2011-9. doi: 10.1200/JCO.2010.33.5091. Epub 2011 Apr 18.
PubMed PMID: 21502544.
 
 
62: Van Cutsem E, Bajetta E, Valle J, Köhne CH, Hecht JR, Moore M, Germond C,
Berg W, Chen BL, Jalava T, Lebwohl D, Meinhardt G, Laurent D, Lin E. Randomized,
placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin
with or without PTK787/ZK 222584 in patients with previously treated metastatic
colorectal adenocarcinoma. J Clin Oncol. 2011 May 20;29(15):2004-10. doi:
10.1200/JCO.2010.29.5436. Epub 2011 Apr 4. PubMed PMID: 21464401.
 
 
63: Asseburg C, Frank M, Köhne CH, Hartmann JT, Griebsch I, Mohr A, Osowski U,
Schulten J, Mittendorf T. Cost-effectiveness of targeted therapy with cetuximab
in patients with K-ras wild-type colorectal cancer presenting with initially
unresectable metastases limited to the liver in a German setting. Clin Ther. 2011
Apr;33(4):482-97. doi: 10.1016/j.clinthera.2011.04.010. PubMed PMID: 21635994.
 
 
64: Kayser S, Döhner K, Krauter J, Köhne CH, Horst HA, Held G, von
Lilienfeld-Toal M, Wilhelm S, Kündgen A, Götze K, Rummel M, Nachbaur D,
Schlegelberger B, Göhring G, Späth D, Morlok C, Zucknick M, Ganser A, Döhner H,
Schlenk RF; German-Austrian AMLSG. The impact of therapy-related acute myeloid
leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood.
2011 Feb 17;117(7):2137-45. doi: 10.1182/blood-2010-08-301713. Epub 2010 Dec 2.
PubMed PMID: 21127174.
 
 
65: Metzner B, Casper J, Hartung G, Rosien B, Hölzle E, Pelzer P, Köhne CH.
Long-term remissions in metastatic malignant melanoma following chemotherapy and
tamoxifen maintenance. Onkologie. 2011;34(4):208-9. doi: 10.1159/000327003. Epub
2011 Mar 18. PubMed PMID: 21447982.
 
 
66: Köhne CH. How to integrate molecular targeted agents in the continuum of
care. Ann Oncol. 2010 Oct;21 Suppl 7:vii134-9. doi: 10.1093/annonc/mdq374.
Review. PubMed PMID: 20943606.
 
 
67: Lugthart S, Gröschel S, Beverloo HB, Kayser S, Valk PJ, van Zelderen-Bhola
SL, Jan Ossenkoppele G, Vellenga E, van den Berg-de Ruiter E, Schanz U, Verhoef
G, Vandenberghe P, Ferrant A, Köhne CH, Pfreundschuh M, Horst HA, Koller E, von
Lilienfeld-Toal M, Bentz M, Ganser A, Schlegelberger B, Jotterand M, Krauter J,
Pabst T, Theobald M, Schlenk RF, Delwel R, Döhner K, Löwenberg B, Döhner H.
Clinical, molecular, and prognostic significance of WHO type
inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute
myeloid leukemia. J Clin Oncol. 2010 Aug 20;28(24):3890-8. doi:
10.1200/JCO.2010.29.2771. Epub 2010 Jul 26. PubMed PMID: 20660833.
 
 
68: Trarbach T, Moehler M, Heinemann V, Köhne CH, Przyborek M, Schulz C, Sneller
V, Gallant G, Kanzler S. Phase II trial of mapatumumab, a fully human agonistic
monoclonal antibody that targets and activates the tumour necrosis factor
apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory
colorectal cancer. Br J Cancer. 2010 Feb 2;102(3):506-12. doi:
10.1038/sj.bjc.6605507. Epub 2010 Jan 12. PubMed PMID: 20068564; PubMed Central
PMCID: PMC2822942.
 
 
69: Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT,
Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch
T, Ockert D, Herrmann T, Goekkurt E, Parisi F, Köhne CH. Tumour response and
secondary resectability of colorectal liver metastases following neoadjuvant
chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol.
2010 Jan;11(1):38-47. doi: 10.1016/S1470-2045(09)70330-4. Epub 2009 Nov 26.
PubMed PMID: 19942479.
 
 
70: Köhne CH, Vanhoefer U, Hartung G. Clinical predictive factors. Eur J Cancer.
2009 Sep;45 Suppl 1:43-9. doi: 10.1016/S0959-8049(09)70015-2. PubMed PMID:
19775603.
 
 
71: Marshall JL, de Gramont A, Köhne CH, Marshall JL, de Gramont A, Köhne CH.
Accomplishments in 2008 in the adjuvant treatment of colon cancer. Gastrointest
Cancer Res. 2009 Sep;3(5 Supplement 2):S2-7. PubMed PMID: 20011560; PubMed
Central PMCID: PMC2791381.
 
 
72: Köhne CH, Lenz HJ. Chemotherapy with targeted agents for the treatment of
metastatic colorectal cancer. Oncologist. 2009 May;14(5):478-88. doi:
10.1634/theoncologist.2008-0202. Epub 2009 May 1. Review. PubMed PMID: 19411318.
 
 
73: Sargent DJ, Köhne CH, Sanoff HK, Bot BM, Seymour MT, de Gramont A, Porschen
R, Saltz LB, Rougier P, Tournigand C, Douillard JY, Stephens RJ, Grothey A,
Goldberg RM. Pooled safety and efficacy analysis examining the effect of
performance status on outcomes in nine first-line treatment trials using
individual data from patients with metastatic colorectal cancer. J Clin Oncol.
2009 Apr 20;27(12):1948-55. doi: 10.1200/JCO.2008.20.2879. Epub 2009 Mar 2.
Erratum in: J Clin Oncol. 2009 Jul 10;27(20):3410-1. PubMed PMID: 19255311;
PubMed Central PMCID: PMC2669760.
 
 
74: Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A,
DHaens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C,
Tejpar S, Schlichting M, Nippgen J, Rougier P. Cetuximab and chemotherapy as
initial treatment for metastatic colorectal cancer. N Engl J Med. 2009 Apr
2;360(14):1408-17. doi: 10.1056/NEJMoa0805019. PubMed PMID: 19339720.
 
 
75: Huebner G, Link H, Kohne CH, Stahl M, Kretzschmar A, Steinbach S, Folprecht
G, Bernhard H, Al-Batran SE, Schoffski P, Burkart C, Kullmann F, Otremba B,
Menges M, Hoffmann M, Kaiser U, Aldaoud A, Jahn A; German CUP Study Group.
Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno-
or undifferentiated carcinoma of unknown primary: a randomised prospective phase
II trial. Br J Cancer. 2009 Jan 13;100(1):44-9. doi: 10.1038/sj.bjc.6604818. Epub
2008 Dec 9. PubMed PMID: 19066607; PubMed Central PMCID: PMC2634671.
 
 
76: Papamichael D, Audisio R, Horiot JC, Glimelius B, Sastre J, Mitry E, Van
Cutsem E, Gosney M, Köhne CH, Aapro M; SIOG. Treatment of the elderly colorectal
cancer patient: SIOG expert recommendations. Ann Oncol. 2009 Jan;20(1):5-16. doi:
10.1093/annonc/mdn532. Epub 2008 Oct 15. Review. PubMed PMID: 18922882.
 
 
77: Bernhard J, Dietrich D, Scheithauer W, Gerber D, Bodoky G, Ruhstaller T,
Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi BC,
Köhne CH, Mingrone W, Stemmer SM, Tàmas K, Kornek GV, Koeberle D, Herrmann R;
Central European Cooperative Oncology Group. Clinical benefit and quality of life
in patients with advanced pancreatic cancer receiving gemcitabine plus
capecitabine versus gemcitabine alone: a randomized multicenter phase III
clinical trial--SAKK 44/00-CECOG/PAN.1.3.001. J Clin Oncol. 2008 Aug
1;26(22):3695-701. doi: 10.1200/JCO.2007.15.6240. PubMed PMID: 18669454.
 
 
78: Köhne CH, De Greve J, Hartmann JT, Lang I, Vergauwe P, Becker K, Braumann D,
Joosens E, Müller L, Janssens J, Bokemeyer C, Reimer P, Link H, Späth-Schwalbe E,
Wilke HJ, Bleiberg H, Van Den Brande J, Debois M, Bethe U, Van Cutsem E.
Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine
plus celecoxib or placebo in the first-line treatment of patients with metastatic
colorectal cancer. EORTC study 40015. Ann Oncol. 2008 May;19(5):920-6. Epub 2007
Dec 6. PubMed PMID: 18065406.
 
 
79: Köhne CH, Folprecht G, Goldberg RM, Mitry E, Rougier P. Chemotherapy in
elderly patients with colorectal cancer. Oncologist. 2008 Apr;13(4):390-402. doi:
10.1634/theoncologist.2007-0043. PubMed PMID: 18448553.
 
 
80: Folprecht G, Seymour MT, Saltz L, Douillard JY, Hecker H, Stephens RJ,
Maughan TS, Van Cutsem E, Rougier P, Mitry E, Schubert U, Köhne CH.
Irinotecan/fluorouracil combination in first-line therapy of older and younger
patients with metastatic colorectal cancer: combined analysis of 2,691 patients
in randomized controlled trials. J Clin Oncol. 2008 Mar 20;26(9):1443-51. doi:
10.1200/JCO.2007.14.0509. PubMed PMID: 18349394.
 
 
81: Folprecht G, Tabernero J, Köhne CH, Zacharchuk C, Paz-Ares L, Rojo F, Quinn
S, Casado E, Salazar R, Abbas R, Lejeune C, Marimón I, Andreu J, Ubbelohde U,
Cortes-Funes H, Baselga J. Phase I pharmacokinetic/pharmacodynamic study of
EKB-569, an irreversible inhibitor of the epidermal growth factor receptor
tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin
(FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer.
Clin Cancer Res. 2008 Jan 1;14(1):215-23. doi: 10.1158/1078-0432.CCR-07-1053.
PubMed PMID: 18172273.
 
 
82: Van Cutsem E, Van de Velde C, Roth A, Lordick F, Köhne CH, Cascinu S, Aapro
M; European Organisation for Research and Treatment of Cancer
(EORTC)-gastrointestinal cancer group. Expert opinion on management of gastric
and gastro-oesophageal junction adenocarcinoma on behalf of the European
Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer
group. Eur J Cancer. 2008 Jan;44(2):182-94. PubMed PMID: 18093827.
 
 
83: Bruce C, Köhne CH, Audisio RA. Treatment of advanced colorectal cancer in the
elderly. Eur J Surg Oncol. 2007 Dec;33 Suppl 2:S84-7. Epub 2007 Nov 19. Review.
PubMed PMID: 18006266.
 
 
84: Sorbye H, Köhne CH, Sargent DJ, Glimelius B. Patient characteristics and
stratification in medical treatment studies for metastatic colorectal cancer: a
proposal for standardization of patient characteristic reporting and
stratification. Ann Oncol. 2007 Oct;18(10):1666-72. Epub 2007 Jul 28. PubMed
PMID: 17660495.
 
 
85: Nordlinger B, Van Cutsem E, Rougier P, Köhne CH, Ychou M, Sobrero A, Adam R,
Arvidsson D, Carrato A, Georgoulias V, Giuliante F, Glimelius B, Golling M,
Gruenberger T, Tabernero J, Wasan H, Poston G; European Colorectal Metastases
Treatment Group. Does chemotherapy prior to liver resection increase the
potential for cure in patients with metastatic colorectal cancer? A report from
the European Colorectal Metastases Treatment Group. Eur J Cancer. 2007
Sep;43(14):2037-45. Epub 2007 Sep 4. Review. PubMed PMID: 17766104.
 
 
86: Punt CJ, Buyse M, Köhne CH, Hohenberger P, Labianca R, Schmoll HJ, Påhlman L,
Sobrero A, Douillard JY. Endpoints in adjuvant treatment trials: a systematic
review of the literature in colon cancer and proposed definitions for future
trials. J Natl Cancer Inst. 2007 Jul 4;99(13):998-1003. Epub 2007 Jun 27. Review.
PubMed PMID: 17596575.
 
 
87: Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J,
Saletti P, Bauer J, Figer A, Pestalozzi B, Köhne CH, Mingrone W, Stemmer SM,
Tàmas K, Kornek GV, Koeberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W;
Swiss Group for Clinical Cancer Research; Central European Cooperative Oncology
Group. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced
pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group
for Clinical Cancer Research and the Central European Cooperative Oncology Group.
J Clin Oncol. 2007 Jun 1;25(16):2212-7. PubMed PMID: 17538165.
 
 
88: Fensterer H, Radlwimmer B, Sträter J, Buchholz M, Aust DE, Julié C, Radvanyi
F, Nordlinger B, Belluco C, Van Cutsem E, Köhne CH, Kestler HA, Schwaenen C,
Nessling M, Lutz MP, Lichter P, Gress TM; EORTC Gastrointestinal (GI) Group.
Matrix-comparative genomic hybridization from multicenter formalin-fixed
paraffin-embedded colorectal cancer tissue blocks. BMC Cancer. 2007 Apr 2;7:58.
PubMed PMID: 17407575; PubMed Central PMCID: PMC3225877.
 
 
89: Boeck S, Weigang-Köhler K, Fuchs M, Kettner E, Quietzsch D, Trojan J, Stötzer
O, Zeuzem S, Lordick F, Köhne CH, Kröning H, Steinmetz T, Depenbrock H, Heinemann
V. Second-line chemotherapy with pemetrexed after gemcitabine failure in patients
with advanced pancreatic cancer: a multicenter phase II trial. Ann Oncol. 2007
Apr;18(4):745-51. Epub 2007 Jan 17. PubMed PMID: 17229775.
 
 
90: Folprecht G, Köhne CH, Lutz MP. Systemic chemotherapy in patients with
peritoneal carcinomatosis from colorectal cancer. Cancer Treat Res.
2007;134:425-40. Review. PubMed PMID: 17633071.
 
 
91: Van Cutsem E, Nordlinger B, Adam R, Köhne CH, Pozzo C, Poston G, Ychou M,
Rougier P; European Colorectal Metastases Treatment Group. Towards a pan-European
consensus on the treatment of patients with colorectal liver metastases. Eur J
Cancer. 2006 Sep;42(14):2212-21. Epub 2006 Aug 10. Review. PubMed PMID: 16904315.
 
 
92: Köhne CH. Should adjuvant chemotherapy become standard treatment for patients
with stage II colon cancer? Against the proposal. Lancet Oncol. 2006
Jun;7(6):516-7. PubMed PMID: 16767832.
 
 
93: Folprecht G, Lutz MP, Schöffski P, Seufferlein T, Nolting A, Pollert P, Köhne
CH. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination
for the first-line treatment of patients with epidermal growth factor receptor
expressing metastatic colorectal carcinoma. Ann Oncol. 2006 Mar;17(3):450-6. Epub
2005 Nov 22. PubMed PMID: 16303861.
 
 
94: Babatz J, Röllig C, Löbel B, Folprecht G, Haack M, Günther H, Köhne CH,
Ehninger G, Schmitz M, Bornhäuser M. Induction of cellular immune responses
against carcinoembryonic antigen in patients with metastatic tumors after
vaccination with altered peptide ligand-loaded dendritic cells. Cancer Immunol
Immunother. 2006 Mar;55(3):268-76. Epub 2005 Jul 21. PubMed PMID: 16034561.
 
 
95: Köhne CH, Folprecht G. On prejudice and facts and choices. Ann Oncol. 2006
Feb;17(2):185-7. PubMed PMID: 16428244.
 
 
96: Efficace F, Bottomley A, Coens C, Van Steen K, Conroy T, Schöffski P, Schmoll
H, Van Cutsem E, Köhne CH. Does a patients self-reported health-related quality
of life predict survival beyond key biomedical data in advanced colorectal
cancer? Eur J Cancer. 2006 Jan;42(1):42-9. Epub 2005 Nov 18. Erratum in: Eur J
Cancer. 2007 Feb;43(3):633. PubMed PMID: 16298522.
 
 
97: Folprecht G, Köhne CH. Drug Insight: Metastatic colorectal cancer--oral
fluoropyrimidines and new perspectives in the adjuvant setting. Nat Clin Pract
Oncol. 2005 Nov;2(11):578-87. Review. PubMed PMID: 16270098.
 
 
98: Folprecht G, Grothey A, Alberts S, Raab HR, Köhne CH. Neoadjuvant treatment
of unresectable colorectal liver metastases: correlation between tumour response
and resection rates. Ann Oncol. 2005 Aug;16(8):1311-9. Epub 2005 May 3. PubMed
PMID: 15870084.
 
 
99: Köhne CH, van Cutsem E, Wils J, Bokemeyer C, El-Serafi M, Lutz MP, Lorenz M,
Reichardt P, Rückle-Lanz H, Frickhofen N, Fuchs R, Mergenthaler HG, Langenbuch T,
Vanhoefer U, Rougier P, Voigtmann R, Müller L, Genicot B, Anak O, Nordlinger B;
European Organisation for Research and Treatment of Cancer Gastrointestinal
Group. Phase III study of weekly high-dose infusional fluorouracil plus folinic
acid with or without irinotecan in patients with metastatic colorectal cancer:
European Organisation for Research and Treatment of Cancer Gastrointestinal Group
Study 40986. J Clin Oncol. 2005 Aug 1;23(22):4856-65. Epub 2005 Jun 6. PubMed
PMID: 15939923.
 
 
100: Steiner M, Seule M, Steiner B, Bauer I, Freund M, Köhne CH, Schuff-Werner P.
5-Fluorouracil/irinotecan induced lethal toxicity as a result of a combined
pharmacogenetic syndrome: report of a case. J Clin Pathol. 2005 May;58(5):553-5.
PubMed PMID: 15858133; PubMed Central PMCID: PMC1770668.
 
 
101: Aapro MS, Köhne CH, Cohen HJ, Extermann M. Never too old? Age should not be
a barrier to enrollment in cancer clinical trials. Oncologist. 2005
Mar;10(3):198-204. Review. PubMed PMID: 15793223.
 
 
102: Folprecht G, Cunningham D, Ross P, Glimelius B, Di Costanzo F, Wils J,
Scheithauer W, Rougier P, Aranda E, Hecker H, Köhne CH. Efficacy of
5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal
cancer: a pooled analysis of clinical trials. Ann Oncol. 2004 Sep;15(9):1330-8.
PubMed PMID: 15319237.
 
 
103: Köhne CH, Bruce C, Folprecht G, Audisio R. Role of new agents in the
treatment of colorectal cancer. Surg Oncol. 2004 Aug-Nov;13(2-3):75-81. Review.
PubMed PMID: 15572089.
 
 
104: Folprecht G, Köhne CH. [New therapy options in colorectal carcinoma]. Ther
Umsch. 2004 Jun;61(6):373-8. Review. German. PubMed PMID: 15253162.
 
 
105: Schleyer E, Pursche S, Köhne CH, Schuler U, Renner U, Gschaidmeier H,
Freiberg-Richter J, Leopold T, Jenke A, Bonin M, Bergemann T, le Coutre P, Gruner
M, Bornhäuser M, Ottmann OG, Ehninger G. Liquid chromatographic method for
detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in
plasma, urine, cerebrospinal fluid, culture medium and cell preparations. J
Chromatogr B Analyt Technol Biomed Life Sci. 2004 Jan 5;799(1):23-36. PubMed
PMID: 14659433.
 
 
106: Bornhäuser M, Illmer T, Le Coutre P, Pursche J, von Bonin M,
Freiberg-Richter J, Schaich M, Platzbecker U, Thiede C, Ottmann OG, Köhne Ch,
Braess J, Ehninger G, Schleyer E. Imatinib mesylate selectively influences the
cellular metabolism of cytarabine in BCR/ABL negative leukemia cell lines and
normal CD34+ progenitor cells. Ann Hematol. 2004;83 Suppl 1:S61-4. Review. PubMed
PMID: 15124675.
 
 
107: Köhne CH, Folprecht G. Current perspectives in the treatment of metastatic
colorectal cancer. Ann Oncol. 2004;15 Suppl 4:iv43-53. Review. PubMed PMID:
15477334.
 
 
108: Folprecht G, Köhne CH. [Principles of postoperative therapy in rectal
carcinoma]. Chirurg. 2004 Jan;75(1):32-7. German. PubMed PMID: 14740125.
 
 
109: Folprecht G, Köhne CH. The role of new agents in the treatment of colorectal
cancer. Oncology. 2004;66(1):1-17. Review. PubMed PMID: 15031593.
 
 
110: Hartmann JT, Oechsle K, Quietzsch D, Wein A, Hofheinz RD, Honecker F, Nehls
O, Köhne CH, Käfer G, Kanz L, Bokemeyer C. Protracted infusional 5-fluorouracil
plus high-dose folinic acid combined with bolus mitomycin C in patients with
gastrointestinal cancer: a phase I/II dose escalation study. Br J Cancer. 2003
Dec 1;89(11):2051-6. PubMed PMID: 14647137; PubMed Central PMCID: PMC2376864.
 
 
111: Köhne CH. [Palliative therapy of colorectal cancer]. Onkologie. 2003 Dec;26
Suppl 7:41-7. Review. German. PubMed PMID: 14716142.
 
 
112: Köhne CH, Wils J, Lorenz M, Schöffski P, Voigtmann R, Bokemeyer C, Lutz M,
Kleeberg C, Ridwelski K, Souchon R, El-Serafi M, Weiss U, Burkhard O, Rückle H,
Lichnitser M, Langenbuch T, Scheithauer W, Baron B, Couvreur ML, Schmoll HJ;
European Organization of Research and Treatment of Cancer Gastrointestinal Group
Study 40952. Randomized phase III study of high-dose fluorouracil given as a
weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus
leucovorin in advanced colorectal cancer: European organization of Research and
Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol. 2003 Oct
15;21(20):3721-8. Epub 2003 Sep 8. PubMed PMID: 12963704.
 
 
113: Köhne CH, Catane R, Klein B, Ducreux M, Thuss-Patience P, Niederle N, Gips
M, Preusser P, Knuth A, Clemens M, Bugat R, Figer I, Shani A, Fages B, Di Betta
D, Jacques C, Wilke HJ. Irinotecan is active in chemonaive patients with
metastatic gastric cancer: a phase II multicentric trial. Br J Cancer. 2003 Sep
15;89(6):997-1001. PubMed PMID: 12966415; PubMed Central PMCID: PMC2376958.
 
 
114: Kiani A, Köhne CH, Franz T, Passauer J, Haufe T, Gross P, Ehninger G,
Schleyer E. Pharmacokinetics of gemcitabine in a patient with end-stage renal
disease: effective clearance of its main metabolite by standard hemodialysis
treatment. Cancer Chemother Pharmacol. 2003 Mar;51(3):266-70. Epub 2003 Mar 4.
PubMed PMID: 12655447.
 
 
115: Ducreux M, Köhne CH, Schwartz GK, Vanhoefer U. Irinotecan in metastatic
colorectal cancer: dose intensification and combination with new agents,
including biological response modifiers. Ann Oncol. 2003;14 Suppl 2:ii17-23.
Review. PubMed PMID: 12810453.
 
 
116: Honecker F, Köhne CH, Bokemeyer C. Colorectal cancer in the elderly: is
palliative chemotherapy of value? Drugs Aging. 2003;20(1):1-11. Review. PubMed
PMID: 12513112.
 
 
117: Steiner M, Schuff-Werner P, Freund M, Köhne CH. Combined chemotherapy trials
require combined pharmacogenetic approaches. J Clin Oncol. 2002 Mar
1;20(5):1425-6. PubMed PMID: 11870191.
 
 
118: Köhne CH, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E,
Scheithauer W, Rougier P, Palmer M, Wils J, Baron B, Pignatti F, Schöffski P,
Micheel S, Hecker H. Clinical determinants of survival in patients with
5-fluorouracil-based treatment for metastatic colorectal cancer: results of a
multivariate analysis of 3825 patients. Ann Oncol. 2002 Feb;13(2):308-17. PubMed
PMID: 11886010.
 
 
119: Radetzki S, Köhne CH, von Haefen C, Gillissen B, Sturm I, Dörken B, Daniel
PT. The apoptosis promoting Bcl-2 homologues Bak and Nbk/Bik overcome drug
resistance in Mdr-1-negative and Mdr-1-overexpressing breast cancer cell lines.
Oncogene. 2002 Jan 10;21(2):227-38. PubMed PMID: 11803466.
 
 
120: Köhne CH. [Capsule instead of infusion--new oral chemotherapy option].
Krankenpfl J. 2002;40(1-2):42-3. German. PubMed PMID: 12035417.
 
 
121: Van Cutsem E, Douillard JY, Köhne CH. Toxicity of irinotecan in patients
with colorectal cancer. N Engl J Med. 2001 Nov 1;345(18):1351-2. PubMed PMID:
11794165.
 
 
122: Köhne CH, Grothey A, Bokemeyer C, Bontke N, Aapro M. Chemotherapy in elderly
patients with colorectal cancer. Ann Oncol. 2001 Apr;12(4):435-42. Review. PubMed
PMID: 11398873.
 
 
123: Thirion P, Piedbois P, Buyse M, ODwyer PJ, Cunningham D, Man A, Greco FA,
Colucci G, Köhne CH, Di Constanzo F, Piga A, Palmeri S, Dufour P, Cassano A,
Pajkos G, Pensel RA, Aykan NF, Marsh J, Seymour MT; Meta-Analysis Group in
Cancer. Alpha-interferon does not increase the efficacy of 5-fluorouracil in
advanced colorectal cancer. Br J Cancer. 2001 Mar 2;84(5):611-20. PubMed PMID:
11237380; PubMed Central PMCID: PMC2363786.
 
 
124: Lorenz M, Mueller HH, Mattes E, Gassel HJ, Junginger T, Saeger HD, Schramm
H, Staib-Sebler E, Vetter G, Heinrich S, Köhne CH; German Cooperative Group on
Liver Metastases (Arbeitsgruppe Lebermetastasen und -tumoren (ALM) in der
Chirurgischen Arbeitsgemeinschaft Onkologie). Phase II study of weekly 24-hour
intra-arterial high-dose infusion of 5-fluorouracil and folinic acid for liver
metastases from colorectal carcinomas. Ann Oncol. 2001 Mar;12(3):321-5. PubMed
PMID: 11332142.
 
 
125: Junghanss C, Leithäuser M, Wilhelm S, Kleine HD, Knopp A, Decker S, Alscher
A, Casper J, Köhne CH, Freund M. High-dose etoposide phosphate and G-CSF
mobilizes peripheral blood stem cells in patients that previously failed to
mobilize. Ann Hematol. 2001 Feb;80(2):96-102. PubMed PMID: 11261332.
 
 
126: Petrowsky H, Sturm I, Graubitz O, Kooby DA, Staib-Sebler E, Gog C, Köhne CH,
Hillebrand T, Daniel PT, Fong Y, Lorenz M. Relevance of Ki-67 antigen expression
and K-ras mutation in colorectal liver metastases. Eur J Surg Oncol. 2001
Feb;27(1):80-7. PubMed PMID: 11237496.
 
 
127: Benter T, Teichgräber UK, Klühs L, Papadopoulos S, Köhne CH, Felix R, Dörken
B. Anatomical variations in the internal jugular veins of cancer patients
affecting central venous access. Anatomical variation of the internal jugular
vein. Ultraschall Med. 2001 Feb;22(1):23-6. PubMed PMID: 11253552.
 
 
128: Köhne CH, Wils JA, Wilke HJ. Developments in the treatment of gastric cancer
in Europe. Oncology (Williston Park). 2000 Dec;14(12 Suppl 14):22-5. Review.
PubMed PMID: 11200144.
 
 
129: Köhne CH, Peters GJ. UFT: mechanism of drug action. Oncology (Williston
Park). 2000 Oct;14(10 Suppl 9):13-8. Review. PubMed PMID: 11098484.
 
 
130: Kretzschmar A, Reichardt P, Thuss-Patience PC, Hohenberger P, Benter T,
Dörken B, Köhne CH. Weekly 24-hour infusion of high-dose 5-fluorouracil plus
folinic acid in combination with mitomycin C for the treatment of advanced
gastric cancer. Oncology. 2000 Jun;59(1):14-7. PubMed PMID: 10895060.
 
 
131: Lorenz M, Heinrich S, Staib-Sebler E, Köhne CH, Wils J, Nordlinger B, Encke
A. Regional chemotherapy in the treatment of advanced pancreatic cancer--is it
relevant? Eur J Cancer. 2000 May;36(8):957-65. Review. PubMed PMID: 10885598.
 
 
132: Armand JP, Cunningham D, van Cutsem E, Misset JL, Kohne CH. Clinical
advances with topoisomerase I inhibitors in gastrointestinal malignancies.
Anticancer Drugs. 1999 Nov;10 Suppl 1:S5-12. Review. PubMed PMID: 10630362.
 
 
133: Lorenz M, Müller HH, Staib-Sebler E, Vetter G, Gog C, Petrowsky H, Köhne CH.
Relevance of neoadjuvant and adjuvant treatment for patients with resectable
liver metastases of colorectal carcinoma. Langenbecks Arch Surg. 1999
Aug;384(4):328-38. Review. PubMed PMID: 10473852.
 
 
134: Sturm I, Köhne CH, Wolff G, Petrowsky H, Hillebrand T, Hauptmann S, Lorenz
M, Dörken B, Daniel PT. Analysis of the p53/BAX pathway in colorectal cancer: low
BAX is a negative prognostic factor in patients with resected liver metastases. J
Clin Oncol. 1999 May;17(5):1364-74. PubMed PMID: 10334520.
 
 
135: Vanhoefer U, Harstrick A, Köhne CH, Achterrath W, Rustum YM, Seeber S, Wilke
H. Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and
infusional fluorouracil as first-line chemotherapy in patients with advanced
colorectal cancer. J Clin Oncol. 1999 Mar;17(3):907-13. PubMed PMID: 10071283.
 
 
136: Köhne CH, Lorenz M, Herrmann R. Colorectal cancer liver metastasis: local
treatment for a systemic disease? Ann Oncol. 1998 Sep;9(9):967-71. Review. PubMed
PMID: 9818069.
 
 
137: Schöffski P, Freund M, Wunder R, Petersen D, Köhne CH, Hecker H, Schubert U,
Ganser A. Safety and toxicity of amphotericin B in glucose 5% or intralipid 20%
in neutropenic patients with pneumonia or fever of unknown origin: randomised
study. BMJ. 1998 Aug 8;317(7155):379-84. PubMed PMID: 9694753; PubMed Central
PMCID: PMC28631.
 
 
138: Hartmann JT, Köhne CH, Schmoll HJ, Daikeler T, Kanz L, Bokemeyer C. Is
continuous 24-hour infusion of 5-fluorouracil plus high-dose folinic acid
effective in patients with progressive or recurrent colorectal cancer? A phase II
study. Oncology. 1998 Jul-Aug;55(4):320-5. PubMed PMID: 9663421.
 
 
139: Köhne CH, Thuss-Patience P, Friedrich M, Daniel PT, Kretzschmar A, Benter T,
Bauer B, Dietz R, Dörken B. Raltitrexed (Tomudex): an alternative drug for
patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity. Br
J Cancer. 1998 Mar;77(6):973-7. PubMed PMID: 9528843; PubMed Central PMCID:
PMC2150099.
 
 
140: Köhne CH, Schöffski P, Wilke H, Käufer C, Andreesen R, Ohl U, Klaasen U,
Westerhausen M, Hiddemann W, Schott G, Harstick A, Bade J, Horster A, Schubert U,
Hecker H, Dörken B, Schmoll HJ. Effective biomodulation by leucovorin of
high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a
randomized trial in patients with advanced colorectal cancer. J Clin Oncol. 1998
Feb;16(2):418-26. PubMed PMID: 9469324.
 
 
141: Lorenz M, Staib-Sebler E, Gog C, Petrowsky H, Köhne CH, Encke A. A pilot
study on intensive weekly 24-hour intra-arterial infusion with 5-fluorouracil and
folinic acid for colorectal liver metastases. Oncology. 1998 Jan-Feb;55(1):53-8.
PubMed PMID: 9428376.
 
 
142: Köhne CH, Harstrick A, Hiddemann W, Schöffski P, Wilke H, Bokemeyer C,
Dörken B, Schmoll HJ. Modulation of 5-fluorouracil with methotrexate and low-dose
N-(phosphonacetyl)-L-aspartate in patients with advanced colorectal cancer.
Results of a phase II study. Eur J Cancer. 1997 Oct;33(11):1896-9. PubMed PMID:
9470854.
 
 
143: Kretzschmar A, Köhne CH, Dörken B. [Docetaxel in treatment of other solid
tumors]. Med Klin (Munich). 1997 Sep 15;92 Suppl 4:16-22. Review. German. PubMed
PMID: 9446015.
 
 
144: Harstrick A, Köhne CH, Hiddemann W, Preusser P, Strumberg D, Berns T, Seeber
S, Wilke H, Schmoll HJ. Modulation of 5-fluorouracil with methotrexate and
low-dose N-(phosphonacetyl)-L-aspartate (PALA) is inactive in advanced pancreatic
carcinoma. Ann Oncol. 1997 Sep;8(9):917-8. PubMed PMID: 9358946.
 
 
145: Köhne CH, Benter T. [After-care of colorectal carcinoma--value of tumor
markers]. Internist (Berl). 1997 Apr;38(4):363-5. German. PubMed PMID: 9213578.
 
 
146: Köhne CH, Wilke H, Hiddemann W, Bokemeyer C, Lohrmann HP, Bodenstein H,
Preiss J, Rauschecker H, Hill H, Kaufer C, Fischer JT, Ohl U, Urbanitz D,
Balleisen L, Schmoll HJ. Phase II evaluation of 5-fluourouracil plus folinic acid
and alpha 2b-interferon in metastatic colorectal cancer. Oncology. 1997
Mar-Apr;54(2):96-101. PubMed PMID: 9075778.
 
 
147: Köhne CH, Daniel PT, Dörken B. The value of weekly high dose infusional
5-fluorouracil in the treatment of advanced colorectal cancer. Tumori. 1997
Jan-Feb;83(1 Suppl):S56-60. PubMed PMID: 9154070.
 
 
148: Cohen AM, Kemeny NE, Köhne CH, Wils J, de Takats PG, Kerr DJ. Is
intra-arterial chemotherapy worthwhile in the treatment of patients with
unresectable hepatic colorectal cancer metastases? Eur J Cancer. 1996
Dec;32A(13):2195-205. Review. PubMed PMID: 9038600.
 
 
149: Bokemeyer C, Kuczyk MA, Köhne CH, Haupt A, Schmoll HJ. [Risk of secondary
neoplasia after treatment of malignant germ cell tumors of the testis]. Med Klin
(Munich). 1996 Nov 15;91(11):703-10. Review. German. PubMed PMID: 9036294.
 
 
150: Köhne CH, Wilke H, Schöffski P, Schmoll HJ. The dead end of 5-fluorouracil
double modulation and promise of continuous infusion schedules in the treatment
of metastatic colorectal cancer. J Infus Chemother. 1996 Fall;6(4):206-10.
Review. PubMed PMID: 9229317.
 
 
151: Köhne CH. [Progress in development of chemotherapy of colorectal carcinoma].
Med Klin (Munich). 1996 Apr 12;91 Suppl 3:33-7. German. PubMed PMID: 8692117.
 
 
152: Köhne CH, Wilke H, Hecker H, Schöffski P, Käufer C, Rauschecker H, Andreesen
R, Ohl U, Lange HJ, Klaassen U, et al. Interferon-alpha does not improve the
antineoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid
in advanced colorectal cancer. First results of a randomized multicenter study by
the Association of Medical Oncology of the German Cancer Society (AIO). Ann
Oncol. 1995 May;6(5):461-6. PubMed PMID: 7669711.
 
 
153: Köhne CH, Hiddemann W, Schüller J, Weiss J, Lohrmann HP, Schmitz-Hübner U,
Bodenstein H, Schöber C, Wilke H, Grem J, et al. Failure of orally administered
dipyridamole to enhance the antineoplastic activity of fluorouracil in
combination with leucovorin in patients with advanced colorectal cancer: a
prospective randomized trial. J Clin Oncol. 1995 May;13(5):1201-8. PubMed PMID:
7738622.
 

Klinikum Oldenburg | Medizinischer Campus Universität Oldenburg

Karriereportal

Jobs.
Karriere.
Ausbildung.
Jetzt bewerben >

Hinweis: Die aufgeführten Qualifikationen, Publikationen und Werdegänge unserer Mitarbeiter sind nicht unbedingt umfassend/vollständig aufgeführt.